TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Klotho Neurosciences ( (KLTO) ) has issued an update.
On July 22, 2025, Klotho Neurosciences announced a partnership with AAVnerGene Inc. to advance its gene therapy candidates using AAVnerGene’s cutting-edge AAV manufacturing and delivery technologies. This collaboration aims to enhance the efficiency, cost-effectiveness, and efficacy of Klotho’s therapies for diseases like Alzheimer’s, Parkinson’s, and ALS. The partnership is expected to address current challenges in AAV gene therapy, such as high costs and dose-related toxicity, by leveraging AAVnerGene’s proprietary platforms to improve manufacturing processes and tissue targeting. This strategic move is anticipated to strengthen Klotho’s position in the gene therapy market and potentially bring more affordable and innovative treatments to patients.
More about Klotho Neurosciences
Klotho Neurosciences, Inc. is a biogenetics company focused on developing innovative cell and gene therapies using a protein derived from the patented ‘anti-aging’ human Klotho gene. The company aims to transform the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease through its proprietary cell and gene therapy programs and genomics-based diagnostic assays.
Average Trading Volume: 43,946,194
Technical Sentiment Signal: Buy
Current Market Cap: $67.99M
See more data about KLTO stock on TipRanks’ Stock Analysis page.